Needham & Company Upgrades Intercept Pharmaceuticals (ICPT) to Buy
Tweet Send to a Friend
Needham & Company analyst Alan Carr upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Hold to Buy with a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE